GlassScriptPhysician profile
James P Kerwin
NPI 1942309232
$848.30
in general payments reported to CMS, 2019-2025
13 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2022: $130 · 2023: $14.06 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $163.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $308.40 | 2019-2025 | Rotablator Rotational Atherectomy System Console Kit, General - Stents, Avvigo Guidance System |
| Amgen INC. | $93.06 | 2019 | |
| Glaxosmithkline, LLC. | $86.88 | 2019-2023 | Shingrix |
| Janssen Pharmaceuticals, INC | $75.03 | 2019 | |
| Pfizer INC. | $67.40 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.26 | 2019 | |
| Arbor Pharmaceuticals, INC. | $36.68 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.60 | 2019 | |
| Radius Health, INC. | $28.54 | 2019 | |
| Astellas Pharma US INC | $18.26 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.06 | 2019 | |
| Amarin Pharma, INC. | $14.59 | 2019 | |
| Novo Nordisk INC | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kerwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.